Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib Safety and PK in Exudative AMD
NCT00215670Phase 3Completed
- Sponsor
- OSI Eyetech
- Start
- Nov 2002
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
01
Overview
A Phase 3 trial of pegaptanib sodium in exudative age-related macular degeneration, sponsored by OSI Eyetech. Started Nov 2002; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00215670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215670.